查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球視網膜疾病治療市場 2023-2030
市場調查報告書
商品編碼
1380424

全球視網膜疾病治療市場 2023-2030

Global Retinal Disorder Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 198 Pages | 商品交期: 2-3個工作天內

價格

預計在預測期（2023-2030年），全球視網膜疾病治療市場將以11.2%的CAGR成長。在與失明的持久戰中，治療主要視網膜疾病及其相關發病率在過去二十年中一直在穩步成長。黃斑部病變治療視網膜疾病的日益普及是支持全球市場成長的關鍵因素。因此，市場參與者也專注於推出基於黃斑部病變的視網膜疾病治療解決方案，以進一步促進市場成長。例如，2023年2月，生物製藥公司Apellis Pharmaceuticals, Inc.宣布美國（FDA）批准SYFOVRE（TM）（pegcetacoplan注射液）用於治療老年黃斑繼發的地圖樣萎縮（GA）變性（AMD） 。 SYFOVRE 是第一個也是唯一一個獲得 FDA 批准的 GA 治療方法，GA 是導致失明的主要原因，影響著美國超過 100 萬人和全球 500 萬人。

根據國際防盲機構（IAPB）統計，2020年，中國和印度的失明和視力障礙負擔合計佔全球的49.0%，而兩國人口占全球人口的37.0%。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Allergan, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Novartis AG
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Regeneron Pharmaceuticals, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按適應症分類的全球視網膜疾病治療市場
    • 糖尿病性視網膜病變
    • 黃斑部病變
    • 視網膜剝離
    • 視網膜母細胞瘤
    • 其他（糖尿病眼疾、黃斑皺襞、黃斑裂孔、飛蚊症）
  • 按劑型分類的全球視網膜疾病治療市場
    • 凝膠
    • 眼睛解決方案
    • 膠囊和片劑
    • 眼藥水
    • 藥膏
  • 按配銷通路的全球視網膜疾病治療市場
    • 醫院藥房
    • 零售藥局
    • 網上銷售

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Adverum Biotechnologies
  • Aldeyra Therapeutics, Inc.
  • Alimera Sciences Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Graybug Vision, Inc.
  • Gyroscope Therapeutics Holdings PLC
  • Iveric Bio, Inc.
  • Kala Pharmaceuticals
  • Kodiak Sciences
  • Otsuka Pharmaceutical Co Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Sentis Pharma Pvt Ltd.
  • Spark Therapeutics
Product Code: OMR2027833

Title: Global Retinal Disorder Treatment Market Size, Share & Trends Analysis Report by Indication (Diabetic Retinopathy, Macular Degeneration, Retinal Detachment, Retinoblastoma and Other), by Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops and Ointments), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Sales),Forecast Period (2023-2030).

The global retinal disorder treatment market is anticipated to grow at a CAGR of 11.2% during the Forecast Period (2023-2030). Treating the main retinal diseases in the everlasting war against blindness and its associated morbidity has been growing steadily over the last two decades. The growing adoption of macular degeneration treatment for retinal disorder key factor supporting the growth of the market globally. Hence, the market players are also focusing on introducing macular degeneration-based retinal disorder treatment solutions that further bolster the market growth. For instance, in February 2023, Apellis Pharmaceuticals, Inc., a biopharmaceutical company in complement, announced that the US (FDA) approved SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the US and five million people globally.

According to the International Agency for the Prevention of Blindness (IAPB), in 2020, China and India together accounted for 49.0% of the global total burden of blindness and vision impairment, while their populations represent 37.0% of the global population.

Segmental Outlook

The global retinal disorder treatment market is segmented on the indication, dosage form, and distribution channel. Based on the indication, the market is sub-segmented into diabetic retinopathy, macular degeneration, retinal detachment, retinoblastoma and others (diabetic eye disease, macular pucker, macular hole, floaters). Based on the dosage form, the market is sub-segmented into gels, eye solutions, capsules & tablets, eye drops and ointments. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies and online sales. Among the dosage form, the eye solutions sub-segment is anticipated to hold a considerable share of the market owing to the rise in

The Macular Degeneration Sub-Segment is Anticipated to Hold a Considerable Share of the Global Retinal Disorder Treatment Market

Among the Indications, the macular degeneration sub-segment is expected to hold a considerable share of the global retinal disorder treatment market. The segmental growth is attributed to the growing treatments of macular degeneration including nutritional supplements, medications, photodynamic therapy (PDT) and laser therapy. US marks an important moment for patients, healthcare providers, payers, and the entire healthcare system. Patients suffering from retinal vascular disorders now have a more affordable treatment option. For instance, in June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i launched in the US. Healthcare provider engagement, promotional activity, and collaborations with professional societies and patient advocacy groups have commenced and BYOOVIZ is commercially available through major distributors across the US.

Regional Outlook

The global retinal disorder treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the growing geriatric population, the increasing launch of novel products, and enhanced awareness levels about eye conditions. The key market players include AbbVie Inc., Genentech, Inc., Graybug Vision, Inc., Ocular Therapeutix, Regeneron Pharmaceuticals, Inc. others.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Retinal Disorder Treatment Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to high healthcare expenditure and good-quality medical facilities. The increasing awareness among the population about early diagnosis & treatment, rising disposable income, and availability of effective and efficient treatment methods. For instance, as of 2021, India has 74 million diabetics, while 12.5 million of these suffer from diabetic retinopathy of some form. Thus, the presence of a high number of target patients is creating opportunities in the region.

Age-related macular degeneration treatment is expected to exhibit lucrative growth, as multiple market players are increasingly focusing on R&D to develop innovative treatments. The key market players include Kubota Pharmaceutical Holdings Co., Ltd., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Senju Pharmaceutical Co., Ltd., Sentis Pharma Pvt Ltd., Sun Pharmaceutical Industries Ltd. and others.

Market Players Outlook

The major companies serving the retinal disorder treatment market include: Allergan, Inc., Bausch Health Companies Inc., Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, AbbVie collaborated with RegenxBio to develop and market a potential one-time gene therapy, RGX-314, for treating wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global retinal disorder treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Allergan, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Novartis AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Regeneron Pharmaceuticals, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Retinal Disorder Treatment Market by Indication
    • 4.1.1. Diabetic Retinopathy
    • 4.1.2. Macular Degeneration
    • 4.1.3. Retinal Detachment
    • 4.1.4. Retinoblastoma
    • 4.1.5. Other (Diabetic Eye Disease, Macular Pucker, Macular Hole, Floaters)
  • 4.2. Global Retinal Disorder Treatment Market by Dosage Form
    • 4.2.1. Gels
    • 4.2.2. Eye Solutions
    • 4.2.3. Capsules & Tablets
    • 4.2.4. Eye Drops
    • 4.2.5. Ointments
  • 4.3. Global Retinal Disorder Treatment Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. Online Sales

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Adverum Biotechnologies
  • 6.2. Aldeyra Therapeutics, Inc.
  • 6.3. Alimera Sciences Inc.
  • 6.4. Bausch Health Companies Inc.
  • 6.5. Biogen Inc.
  • 6.6. Clearside Biomedical, Inc.
  • 6.7. F. Hoffmann-La Roche AG
  • 6.8. Genentech, Inc.
  • 6.9. Graybug Vision, Inc.
  • 6.10. Gyroscope Therapeutics Holdings PLC
  • 6.11. Iveric Bio, Inc.
  • 6.12. Kala Pharmaceuticals
  • 6.13. Kodiak Sciences
  • 6.14. Otsuka Pharmaceutical Co Ltd.
  • 6.15. Santen Pharmaceutical Co., Ltd.
  • 6.16. Sentis Pharma Pvt Ltd.
  • 6.17. Spark Therapeutics

LIST OF TABLES

  • 1. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL DIABETIC RETINOPATHY DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RETINAL MACULAR DEGENERATION DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RETINAL DETACHMENT DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL RETINAL RETINOBLASTOMA DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHERS RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 8. GLOBAL GELS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL EYE SOLUTIONS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CAPSULES & TABLETS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL EYE DROPS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL OINTMENTS FOR RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNELS, 2022-2030 ($ MILLION)
  • 14. GLOBAL RETINAL DISORDER TREATMENT IN HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL RETINAL DISORDER TREATMENT IN RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL RETINAL DISORDER TREATMENT IN ONLINE SALES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 22. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 24. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 25. EUROPEAN RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 29. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DOSAGE FORM, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY INDICATION, 2022 VS 2030 (%)
  • 2. GLOBAL DIABETIC RETINOPATHY DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL RETINAL MACULAR DEGENERATION DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RETINAL DETACHMENT DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL RETINOBLASTOMA DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHERS RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY DOSAGE FORM, 2022 VS 2030 (%)
  • 8. GLOBAL GELS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL EYE SOLUTIONS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CAPSULES & TABLETS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL EYE DROPS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OINTMENTS FOR RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 14. GLOBAL RETINAL DISORDER TREATMENT IN HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL RETINAL DISORDER TREATMENT IN RETAIL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL RETINAL DISORDER TREATMENT IN ONLINE SALES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD RETINAL DISORDER TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)